Enoxaparin Sales Data
| Rank 37 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows enoxaparin U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 37 ( 1) |
$341,184 | 6.55% | 4,422 | 15.55% |
| Q3 2013 | 38 ( 5) |
$320,200 | -12.31% | 3,827 | -10.90% |
| Q2 2013 | 33 (3) |
$365,164 | 0.02% | 4,295 | -0.37% |
| Q1 2013 | 36 (5) |
$365,091 | -7.37% | 4,311 | -0.90% |
| Q4 2012 | 31 (1) |
$394,149 | 1.54% | 4,350 | 16.37% |
| Q3 2012 | 30 (3) |
$388,188 | -15.96% | 3,738 | -2.35% |
| Q2 2012 | 27 (3) |
$461,889 | 4.44% | 3,828 | 9.75% |
| Q1 2012 | 30 (4) |
$442,263 | -8.30% | 3,488 | 0.55% |
| Q4 2011 | 26 (12) |
$482,286 | 36.13% | 3,469 | 118.86% |
| Q3 2011 | 38 (1) |
$354,293 | 5.21% | 1,585 | 4.41% |
| Q2 2011 | 39 (8) |
$336,755 | 8.08% | 1,518 | 10.80% |
| Q1 2011 | 47 | $311,579 | n/a | 1,370 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.